FDA Approves First Targeted Therapy for Rare Bile Duct Cancer

For patients with cholangiocarcinoma, a rare and aggressive form of bile duct cancer, hope has arrived in the form of a new targeted therapy. The U.S. Food and Drug Administration (FDA) recently approved Bizengri, an intravenous medication from Partner Therapeutics, for adults whose disease has progressed despite prior treatment. This marks a significant step forward in treating a condition that affects approximately 8,000 people annually in the United States.

Cholangiocarcinoma can be particularly challenging to manage, with a five-year survival rate of about 10% for cases originating within the liver and around 13% for those starting outside the liver. The approval of Bizengri is especially important because it targets a specific genetic mutation known as NRG1 gene fusions, which are found in fewer than 1% of cholangiocarcinoma cases.

A Breakthrough for a Rare Mutation

Bizengri, also known by its scientific name zenocutuzumab (ZBco), is a bispecific antibody designed to bind to the HER3 receptor and prevent it from interacting with NRG1 gene fusions. This mechanism of action is crucial because patients with this specific mutation often lack other cancer drivers, leaving them without approved targeted therapies.

The FDA's decision was based on an open-label clinical trial involving 22 patients with advanced NRG1 fusion-positive cholangiocarcinoma. Among the 19 participants who were evaluable for efficacy, the overall response rate was a promising 36.8%. The duration of these responses ranged from 2.8 to 12.9 months. Common side effects reported in the trial included infusion-related reactions, diarrhea, and muscle pain.

The approval process for Bizengri was notably swift, facilitated by the FDA's Commissioner’s National Priority Voucher (CNPV) pilot program. This initiative aims to expedite the review and approval of treatments for rare or neglected diseases, highlighting the significance of this breakthrough for a patient population with limited options.

What Comes Next

For patients diagnosed with cholangiocarcinoma, the availability of Bizengri represents a new ray of hope. However, the journey does not end here. Patients must first undergo genetic testing to identify whether their cancer is driven by NRG1 gene fusions before they can be considered for this targeted therapy.

While chemotherapy remains the standard first-line treatment for cholangiocarcinoma, it comes with significant toxicity and often yields limited results. Second-line chemotherapy combinations lead to objective responses in only about 5% of patients. Bizengri offers a viable alternative for those who test positive for NRG1 gene fusions, potentially improving both quality of life and survival outcomes.

The approval of Bizengri also underscores the importance of ongoing research into targeted therapies for rare cancers. As genetic testing becomes more accessible and precise, the potential to identify and treat specific mutations will continue to grow, offering hope to many who have long been underserved by existing treatments.

For now, the focus remains on ensuring that eligible patients can access this new therapy and benefit from its promising results. The medical community is closely monitoring the impact of Bizengri in real-world settings, with an eye toward further refining treatment protocols and expanding options for all cholangiocarcinoma patients.